Air Date: September 5, 2024
1:00 PM ET
There continues to be great uncertainty and worry concerning the FDA’s 2024 final rule to regulate laboratory-developed tests (LDTs). Of particular concern is how the rule may affect oncology labs that previously created LDTs. Many labs may have questions related to data collection, filings, and costs.
During this free webinar, attendees will get answers to the following key questions:
- How does the final rule apply to oncology LDTs?
- What does the rule mean for precision medicine efforts in cancer diagnosis and treatment?
- What are the upcoming timelines for the final rule?
Join G2 Intelligence and our sibling brand, Today’s Clinical Lab, along with expert speaker Sheila D. Walcoff, JD, to get clarification on the key issues related to oncology LDTs.